BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Press Releases

  Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

  April 22, 2026

   · 

  2 min read
• Press Releases

  Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701

  April 22, 2026

   · 

  4 min read
• Press Releases

  Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines

  April 22, 2026

   · 

  7 min read
• 

  Business

  Lilly exits Rigel alliance, adding to RIPK1 scrap heap

  Eli Lilly and Rigel Pharmaceuticals partnered in February 2021 to advance a pair of RIPK1 blockers, but the pharma in October last year pulled the plug on one of these programs for central nervous system indications.

  April 22, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Press Releases

  Restart Life Sciences Provides Performance and Revenue Trend Update on Newly Acquired Superseed Cereals and Oatmeal Brand Portfolio

  April 22, 2026

   · 

  6 min read
• Press Releases

  Envoy Medical Reaches Critical Milestone in Pivotal Clinical Trial of Fully Implanted Acclaim(R) Cochlear Implant

  All 56 Enrolled Subjects Have Been Through Their Activation Visit Firming Up Study Timeline

  April 22, 2026

   · 

  7 min read
• Press Releases

  Trenchant Technologies Capital Corp. Completes Unwinding of Previous Limitless Quantum Acquisition and Corporate Updates

  April 22, 2026

   · 

  5 min read
• 

  rare diseases

  Ionis’ antisense drug stabilizes ultra-rare disease ahead of FDA decision

  The pivotal study of zilganersen in Alexander disease missed a secondary endpoint, but analysts expect the FDA to approve the asset given the unmet need and overall data.

  April 22, 2026

   · 

  2 min read

   · 

  Nick Paul Taylor
• 

  Psychedelics

  Trump’s psychedelics push a mixed blessing for neuropsychiatric companies, patients

  With a greenlight for ibogaine to enter clinical testing and three unnamed products set to receive Commissioner’s National Priority Vouchers this week, it’s full speed ahead for psychedelics. But will sidestepping normal regulatory protocols actually be a net negative for the field?

  April 22, 2026

   · 

  8 min read

   · 

  Heather McKenzie
• 

  Manufacturing

  FDA issues warning letter after GLP-1 manufacturer refuses inspectors access

  New Life told FDA inspectors that they lacked the authority to enter parts of a facility where it made the GLP-1 receptor agonists semaglutide and tirzepatide.

  April 22, 2026

   · 

  2 min read

   · 

  Nick Paul Taylor